Merck to Discontinue Development of MK-7110 for COVID-19
15 Abril 2021 - 7:46AM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced the discontinuation of development of
MK-7110 (formerly known as CD24Fc) for the treatment of
hospitalized patients with COVID-19.
Merck acquired MK-7110 in December 2020 through its acquisition
of OncoImmune, a privately-held clinical-stage biopharmaceutical
company. As previously reported, Merck subsequently received
feedback from the US Food and Drug Administration that additional
data, beyond the study conducted by OncoImmune, would be needed to
support a potential Emergency Use Authorization application. Based
on the additional research that would be required – new clinical
trials as well as research related to manufacturing at scale –
MK-7110 would not be expected to become available until the first
half of 2022. Given this timeline and these technical, clinical and
regulatory uncertainties, the availability of a number of medicines
for patients hospitalized with COVID-19, and the need to
concentrate Merck’s resources on accelerating the development and
manufacture of the most viable therapeutics and vaccines, Merck has
determined to discontinue development of MK-7110 for COVID-19 and
to focus its pandemic efforts on advancing molnupiravir and on
producing Johnson & Johnson’s COVID-19 vaccine.
“Merck’s commitment from the outset of the pandemic has been to
deploy our expertise and capabilities where they can have the most
impact,” said Dr. Roy Baynes, senior vice president and head of
global clinical development, chief medical officer, Merck Research
Laboratories. “Merck is now focusing its efforts on advancing
molnupiravir, which, as an oral medicine for outpatient use,
represents a promising potential new approach, and on accelerating
production of Johnson & Johnson’s COVID-19 vaccine.”
About Merck
For 130 years, Merck, known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases in
pursuit of our mission to save and improve lives. We demonstrate
our commitment to patients and population health by increasing
access to health care through far-reaching policies, programs and
partnerships. Today, Merck continues to be at the forefront of
research to prevent and treat diseases that threaten people and
animals – including cancer, infectious diseases such as HIV and
Ebola, and emerging animal diseases – as we aspire to be the
premier research-intensive biopharmaceutical company in the world.
For more information, visit www.merck.com and connect with us on
Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the global outbreak of novel coronavirus disease
(COVID-19); the impact of pharmaceutical industry regulation and
health care legislation in the United States and internationally;
global trends toward health care cost containment; technological
advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict
future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and
other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2020
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210415005251/en/
Merck Media Contacts: Ian McConnell (973) 901-5722 Patrick Ryan
(973) 275-7075
Investor Contacts: Peter Dannenbaum (908) 740-1037 Raychel
Kruper (908) 740-2107
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Merck (NYSE:MRK)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024